Relating to health benefit plan coverage for certain biomarker testing.

SB 2674 requires Texas health benefit plans to cover specific biomarker testing for diagnosis, treatment, or monitoring of diseases (including post-transplant care) when supported by evidence like FDA approvals, Medicare guidelines, or clinical standards. It directly affects health insurers and plans sold in Texas, mandating coverage for tests meeting the specified evidence criteria. The law applies only to plans delivered, issued, or renewed on or after January 1, 2026, with implementation delayed if federal waivers are needed. The bill takes effect September 1, 2025, and does not change coverage for plans active before that date.